Citation
Corbett, D, et al. "In Vitro Susceptibility of Clostridium Difficile to SMT19969 and Comparators, as Well as the Killing Kinetics and Post-antibiotic Effects of SMT19969 and Comparators Against C. Difficile." The Journal of Antimicrobial Chemotherapy, vol. 70, no. 6, 2015, pp. 1751-6.
Corbett D, Wise A, Birchall S, et al. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J Antimicrob Chemother. 2015;70(6):1751-6.
Corbett, D., Wise, A., Birchall, S., Warn, P., Baines, S. D., Crowther, G., Freeman, J., Chilton, C. H., Vernon, J., Wilcox, M. H., & Vickers, R. J. (2015). In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. The Journal of Antimicrobial Chemotherapy, 70(6), 1751-6. https://doi.org/10.1093/jac/dkv006
Corbett D, et al. In Vitro Susceptibility of Clostridium Difficile to SMT19969 and Comparators, as Well as the Killing Kinetics and Post-antibiotic Effects of SMT19969 and Comparators Against C. Difficile. J Antimicrob Chemother. 2015;70(6):1751-6. PubMed PMID: 25652750.
TY - JOUR
T1 - In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.
AU - Corbett,D,
AU - Wise,A,
AU - Birchall,S,
AU - Warn,P,
AU - Baines,S D,
AU - Crowther,G,
AU - Freeman,J,
AU - Chilton,C H,
AU - Vernon,J,
AU - Wilcox,M H,
AU - Vickers,R J,
Y1 - 2015/02/03/
PY - 2014/10/24/received
PY - 2014/12/31/accepted
PY - 2015/2/6/entrez
PY - 2015/2/6/pubmed
PY - 2016/2/6/medline
KW - C. difficile
KW - PAE
KW - antimicrobial
SP - 1751
EP - 6
JF - The Journal of antimicrobial chemotherapy
JO - J Antimicrob Chemother
VL - 70
IS - 6
N2 - OBJECTIVES: SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostridium difficile infection (CDI). The objective was to determine the comparative susceptibility of 82 C. difficile clinical isolates (which included ribotype 027 isolates and isolates with reduced metronidazole susceptibility) to SMT19969, fidaxomicin, vancomycin and metronidazole and to determine the killing kinetics and post-antibiotic effects of SMT19969, fidaxomicin and vancomycin against C. difficile. METHODS: MICs were determined by agar incorporation. Killing kinetics and post-antibiotic effects were determined against C. difficile BI1, 630 and 5325 (ribotypes 027, 012 and 078, respectively). RESULTS: SMT19969 showed potent inhibition of C. difficile (MIC90=0.125 mg/L) and was markedly more active than either metronidazole (MIC90 = 8 mg/L) or vancomycin (MIC90 = 2 mg/L). There were no differences in susceptibility to SMT19969 between different ribotypes. Fidaxomicin was typically one doubling dilution more active than SMT19969 and both agents maintained activity against isolates with reduced susceptibility to metronidazole. In addition, SMT19969 was bactericidal against the C. difficile strains tested, with reductions in viable counts to below the limit of detection by 24 h post-inoculation. Vancomycin was bacteriostatic against all three strains. Fidaxomicin was bactericidal although reduced killing was observed at concentrations <20 × MIC against C. difficile BI1 (ribotype 027) compared with other strains tested. CONCLUSIONS: These data demonstrate that SMT19969 is associated with potent and bactericidal activity against the strains tested and support further investigation of SMT19969 as potential therapy for CDI.
SN - 1460-2091
UR - https://www.unboundmedicine.com/medline/citation/25652750/In_vitro_susceptibility_of_Clostridium_difficile_to_SMT19969_and_comparators_as_well_as_the_killing_kinetics_and_post_antibiotic_effects_of_SMT19969_and_comparators_against_C__difficile_
L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkv006
DB - PRIME
DP - Unbound Medicine
ER -